TOP-5 Price Targets by Analysts on 22.01.25
Reading Time: 2 minutes
Evolus Inc. [US30052C1071]: Stifel reiterates Buy rating with a price target of 25 USD (84% upside potential) Evolus operates in the field of aesthetic medicine, particularly skin rejuvenation and wrinkle treatment. The company not only sells aesthetic medical products, but also provides training and support for beauty clinics to optimize product usage. The analyst from Stifel highlights that despite some concerns, the company has recorded strong revenue growth of 32% in 2024 and is well-positioned with positive cash flow and a growing customer...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
